Replies to post #102345 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

From ONPH 12-9-21 year end Review
During this past year Oncology Pharma has also signed license agreements with Regen BioPharma, Inc. for its small molecule and for the mRNA technology to address colon cancer and pancreatic cancer. It is the Company's intent that in the beginning of next year it will further engage with our team to advance these licenses along the same path as we have with the nanoemulsion of dactinomycin.

[Jack Torrance]

If Oncology Pharma doesn't do anything with the agreement on time, and their ability to license the patents is null and void, then this might open the way to a Regen buyout. I know a big pharma would much more like to be able to buy all the I.P., lock stock and barrel, rather than have to deal with a licensing agreement. Because any big pharma company will want the I.P. all for themselves.